dr. stinchcombe on the alta-1l trial in alk nsclc
Published 4 years ago • 82 plays • Length 0:56Download video MP4
Download video MP3
Similar videos
-
0:52
dr. stinchcombe on the benefit of alectinib in alk nsclc
-
1:05
dr. stinchcombe on molecular testing in alk nsclc
-
1:32
dr. stinchcombe on remaining challenges in alk nsclc
-
1:08
dr. stinchcombe on the keynote-189 trial in lung cancer
-
1:10
dr. stinchcombe on advances in targeted therapies in nsclc
-
6:58
alta-1l: brigatinib versus crizotinib for alk nsclc
-
0:53
dr. stinchcombe discusses differences in toxicity profiles among alk inhibitors in nsclc
-
5:51
alta-1l: brigatinib vs crizotinib for alk advanced non small cell lung cancer patients
-
1:22
dr. campelo on the rationale for the alta-1l trial
-
0:51
dr. stinchcombe discusses the pacific trial for nsclc
-
2:05
alta-1l: brigatinib vs crizotinib in nsclc
-
8:16
alta ii trial of brigatinib in alk-rearranged nsclc
-
4:00
alta-1l: final overall survival results of brigatinib vs crizotinib for alk lung cancer
-
4:38
alta ii: brigatinib in crizotinib-resistant alk nsclc
-
2:18
alta-1l: brigatinib is superior to crizotinib in alk nsclc
-
2:09
alta-1l: brigatinib vs crizotinib in alk ansclc
-
5:44
updates in alk lung cancer: glass, alex, alta-1l and crown
-
1:37
dr. camidge on the alex trial in patients with alk nsclc
-
1:39
dr. leach on brigatinib in alk-positive nsclc